Results of Adjunctive Intraoperative Bevacizumab Injection on Trabeculectomy Outcome
- Registration Number
- NCT01263834
- Lead Sponsor
- Prince of Songkla University
- Brief Summary
The purpose of this study is to evaluate the adjunctive effect of intratenon Bevacizumab on the result of trabeculectomy in primary term of intraocular pressure (IOP).
- Detailed Description
Prospective interventional clinical trial
Single center, outcome assessor-masked, active control, randomized controlled trial
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 39
Inclusion Criteria
- Primary open angle glaucoma with primary mmc-trabeculectomy indication
Exclusion Criteria
- combined phacoemulsification with trabeculectomy
- no more than 6 month of cataract surgery before trabeculectomy
- revised trabeculectomy
- active uveitic glaucoma
- neovascular glaucoma
- par planar vitrectomy
- conjunctival surgery
- allergy to bevacizumab or mitomycin C
- ischemic heart disease
- cerebrovascular disease
- renal failure
- liver failure
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Mitomycin c Mitomycin C Mitomycin C soaked cellulose dose 0.4 mg/ml with 3 minutes of application Bevacizumab Bevacizumab Bevacizumab injection of 1.25m/0.05 cc + Mitomycin C soaked cellulose dose 0.4 mg/ml with 3 minutes of application
- Primary Outcome Measures
Name Time Method Intraocular pressure 6 month
- Secondary Outcome Measures
Name Time Method Bleb characteristic grading 6 month systemic Blood pressure 6 months
Trial Locations
- Locations (1)
Glaucoma unit , Department of Ophthalmology Faculty of Medicine Prince of Songkla University
🇹🇭Hat-yai, Songkhla, Thailand